13D Filing: Longitude Capital Partners, LLC and Corcept Therapeutics Inc (CORT)

¹ Investment funds from limited
partners were used to acquire the securities over which the Reporting Persons have shared voting and dispositive power.

² Consists of 272,281 shares
of Common Stock held of record by Mr. Enright.

³ Consists of 1,732,985 shares
of Common Stock held of record by LVP, 34,732 shares of Common Stock held of record by LCA and stock options to purchase up to
305,000 shares of Common Stock granted to Mr. Enright, all of which are currently exercisable or exercisable within 60 days
after June 7, 2017.

⁴ The percentage was calculated
based upon 113,497,462 shares of Common Stock outstanding, calculated as follows: the 113,187,462 shares of Common Stock outstanding
as of April 28, 2017, as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the Commission on May 2,
2017, plus the 305,000 shares of Common Stock subject to stock options granted to Mr. Enright that are exercisable as of or
within 60 days after June 7, 2017.